Literature DB >> 12082532

Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers.

Ashraf Dallol1, Eva Forgacs, Alonso Martinez, Yoshitaka Sekido, Rosemary Walker, Takeshi Kishida, Pamela Rabbitts, Eamonn R Maher, John D Minna, Farida Latif.   

Abstract

The human homologue of the Drosophila Roundabout gene DUTT1 (Deleted in U Twenty Twenty) or ROBO1 (Locus Link ID 6091), a member of the NCAM family of receptors, was recently cloned from the lung cancer tumour suppressor gene region 2 (LCTSGR2 or U2020 region) at 3p12. DUTT1 maps within a region of overlapping homozygous deletions characterized in both small cell lung cancer lines (SCLC) and in a breast cancer line. In this report we (a) defined the genomic organization of the DUTT1 gene, (b) performed mutation and expression analysis of DUTT1 in lung, breast and kidney cancers, (c) identified tumour specific promoter region methylation of DUTT1 in human cancers. The gene was found to contain 29 exons and spans at least 240 kb of genomic sequence. The 5' region contains a CpG island, and the poly(A)(+) tail has an atypical 5'-GATAAA-3' signal. We analysed DUTT1 for mutations in lung, breast and kidney cancers, no inactivating mutations were detected by PCR-SSCP. However, seven germline missense changes were found and characterized. DUTT1 expression was not detectable in one out of 18 breast tumour lines analysed by RT-PCR. Bisulfite sequencing of the promoter region of DUTT1 gene in the HTB-19 breast tumour cell line (not expressing DUTT1) showed complete hypermethylation of CpG sites within the promoter region of the DUTT1 gene (-244 to +27 relative to the translation start site). The expression of DUTT1 gene was reactivated in HTB-19 after treatment with the demethylating agent 5-aza-2'-deoxycytidine. The same region was also found to be hypermethylated in six out of 32 (19%) primary invasive breast carcinomas and eight out of 44 (18%) primary clear cell renal cell carcinomas (CC-RCC) and in one out of 26 (4%) primary NSCLC tumours. Furthermore 80% of breast and 75% of CC-RCC tumours showing DUTT1 methylation had allelic losses for 3p12 markers hence obeying Knudson's two hit hypothesis. Our findings suggest that DUTT1 warrants further analysis as a candidate for the tumour suppressor gene (TSG) at 3p12, a region defined by hemi and homozygous deletions and functional analysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082532     DOI: 10.1038/sj.onc.1205421

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

Review 1.  Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes.

Authors:  Gwyndolen C Harburg; Lindsay Hinck
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-08-05       Impact factor: 2.673

2.  Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/β-catenin pathway.

Authors:  Po-Hao Chang; Wendy W Hwang-Verslues; Yi-Cheng Chang; Chun-Chin Chen; Michael Hsiao; Yung-Ming Jeng; King-Jen Chang; Eva Y-H P Lee; Jin-Yuh Shew; Wen-Hwa Lee
Journal:  Cancer Res       Date:  2012-07-23       Impact factor: 12.701

3.  ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.

Authors:  Aijaz Parray; Hifzur R Siddique; Jacquelyn K Kuriger; Shrawan K Mishra; Johng S Rhim; Heather H Nelson; Hiroyuki Aburatani; Badrinath R Konety; Shahriar Koochekpour; Mohammad Saleem
Journal:  Int J Cancer       Date:  2014-04-29       Impact factor: 7.396

Review 4.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

5.  Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis.

Authors:  M Christine Hollander; Robyn T Philburn; Andrew D Patterson; Susana Velasco-Miguel; Errol C Friedberg; R Ilona Linnoila; Albert J Fornace
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

6.  Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.

Authors:  Jason J Northey; Alexander S Barrett; Irene Acerbi; Mary-Kate Hayward; Stephanie Talamantes; Ivory S Dean; Janna K Mouw; Suzanne M Ponik; Jonathon N Lakins; Po-Jui Huang; Junmin Wu; Quanming Shi; Susan Samson; Patricia J Keely; Rita A Mukhtar; Jan T Liphardt; John A Shepherd; E Shelley Hwang; Yunn-Yi Chen; Kirk C Hansen; Laurie E Littlepage; Valerie M Weaver
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

7.  ROBO1 deletion as a novel germline alteration in breast and colorectal cancer patients.

Authors:  Rolando A R Villacis; Francine B Abreu; Priscila M Miranda; Maria A C Domingues; Dirce M Carraro; Erika M M Santos; Victor P Andrade; Benedito M Rossi; Maria I Achatz; Silvia R Rogatto
Journal:  Tumour Biol       Date:  2015-10-01

8.  The Slit receptor Robo1 is predominantly expressed via the Dutt1 alternative promoter in pioneer neurons in the embryonic mouse brain and spinal cord.

Authors:  Hikmet Feyza Nural; W Todd Farmer; Grant S Mastick
Journal:  Gene Expr Patterns       Date:  2007-08-07       Impact factor: 1.224

9.  MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.

Authors:  Jun Tie; Yanglin Pan; Lina Zhao; Kaichun Wu; Jie Liu; Shiren Sun; Xuegang Guo; Biaoluo Wang; Yi Gang; Yongguo Zhang; Quanjiang Li; Taidong Qiao; Qingchuan Zhao; Yongzhan Nie; Daiming Fan
Journal:  PLoS Genet       Date:  2010-03-12       Impact factor: 5.917

10.  Frequent alterations of SLIT2-ROBO1-CDC42 signalling pathway in breast cancer: clinicopathological correlation.

Authors:  Rittwika Bhattacharya; Nupur Mukherjee; Hemantika Dasgupta; Md Saimul Islam; Neyaz Alam; Anup Roy; Priyobrata Das; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  J Genet       Date:  2016-09       Impact factor: 1.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.